Skip to main content
. 2020 Oct 7;9(10):3214. doi: 10.3390/jcm9103214

Figure 2.

Figure 2

Mechanism of acquired resistance to phosphoionositide 3 kinase (PI3K) inhibition (a) Cell viability curves of different head and neck squamous cell carcinoma (HNSCC) and esophageal SCC cell lines (PIK3CA mutated, amplified, and wild type) treated with BYL719. (b) Cell viability curves of Cal33, FaDu, and Cal33-R cell lines treated with BYL719. (c) Signaling pathway protein expression in Cal33, Cal33-R, and FaDu cell lines treated with BYL719. (d) Tumor growth curves of Cal33 and Cal33-R cell line xenografts treated for 27 days with daily oral administration of either 50 mg/kg BYL719 or vehicle (n = 8). (* p < 0.05, ** p < 0.01).